Recent Company News

• 08:41 PM ET May 05, 2026
  

  NICE recommends Pfizer's Braftovi plus Mektovi to treat BRAF V600E mutation-positive advanced NSCLC ($26.45, 0.00)

• 05:21 PM ET Apr 28, 2026
  

  NICE recommends ripretinib (Qinlock) for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors in adults

• 06:20 AM ET Apr 24, 2026
  

  EU's CHMP adopted a positive opinion recommending change to the terms of the marketing authorisation for Opdivo ($59.02, 0.00)

• 04:59 PM ET Apr 22, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:00 AM ET Apr 22, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:17 AM ET Apr 22, 2026
  

  Inhibrx Biosciences' INBRX-106 said to draw interest from Merck (MRK), Merck KGaA (MRK.GR), Ono Pharma (4528.JP) -- Reuters ($84.08, 0.00)

• 04:49 PM ET Mar 20, 2026
  

  Bristol Myers Squibb announces that Opdivo (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and the European Union (EU) ($57.48, 0.00)

• 02:00 PM ET Mar 09, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 2-Mar

• 08:55 AM ET Mar 03, 2026
  

  Sinopia Biosciences (private) announces drug discovery collaboration with Ono Pharmaceutical for rare metabolic disorders (¥2488.0000, 0)

• 08:02 PM ET Mar 02, 2026
  

  Ono Pharmaceutical to expand drug discovery collaboration agreement with Congruence Therapeutic (¥2502.5000, -41)